An oil processing facility at Abqaiq and the nearby Khurais oil field was attacked on Saturday.Marketsread more
"There is reason to believe that we know the culprit," Trump said in a post on Twitter.Politicsread more
Brent crude surged by as much as 19.5% to reach $71.95 per barrel on Monday, the biggest intra-day jump since the Gulf War in 1991.Oilread more
The strike, depending on its length, could easily cost GM hundreds of millions of dollars. The last time the union declared a strike at GM was in 2007.Autosread more
Saudi Aramco has 35-40 days of supply to meet contractual obligations, a source close to the matter told CNBC.Energyread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
OxyContin maker Purdue Pharma filed for Chapter 11 bankruptcy protection on Sunday.Health and Scienceread more
Saudi Arabia on Saturday shut down half its oil production after a series of drone strikes hit the world's largest oil processing facility in an attack claimed by Yemen's...Futures & Commoditiesread more
U.S. stock futures sank amid fears that a surge in oil prices following an attack in Saudi Arabia could slow down global economic growth.Marketsread more
The recommendations include changing corporate reporting structures, creating a new safety group, and changing the cockpits of future planes to accommodate new pilots with...Aerospace & Defenseread more
The state would become the second in the country, behind Michigan, to ban the sale of fruit flavored e-cigarettes, which are popular with teenagers.Health and Scienceread more
Acadia Pharmaceuticals fell more than 22 percent in after-hours trading Wednesday on news that its CEO is retiring.
The bio-pharmaceutical company announced Wednesday afternoon that Uli Hacksell retired as both its CEO and a member of its board of directors, effective immediately. Chief Financial Officer Steve Davis would take over as interim CEO, the company said.
Separately, Acadia announced Wednesday that it would change the timing of its planned New Drug Application (NDA) submission for Nuplazid to the second half of the year. The company had originally planned to submit the application in the first quarter.
Acadia said it planned to hold a 5 p.m. ET conference call on Wednesday "to discuss its planned NDA submission and the management change."
Nuplazid is a drug potentially positioned "to be the only drug approved in the United States for psychosis associated with Parkinson's disease," according to Acadia's website.
Including Wednesday's after-hours trade, Acadia stock is up about 2,000 percent over past three years.
—Reuters contributed to this report.